Evicenter
P&T meetings

Dersimelagon

Erythropoietic protoporphyria or X-linked protoporphyria

Also known as MT-7117
Manufacturer
LEO Pharma
Regulatory submission
NDA submitted June 2026
100 sources

Section 6 of 6

References

100 sources

  1. Balwani (2019) (opens in a new tab)
  2. Balwani and Desnick (2019) (opens in a new tab)
  3. Balwani et al. (2017a) (opens in a new tab)
  4. Balwani et al. (2017b) (opens in a new tab)
  5. Balwani et al. (2020) (opens in a new tab)
  6. Balwani et al. (2023) (opens in a new tab)
  7. Barman-Aksözen et al. (2020) (opens in a new tab)
  8. Barman-Aksözen et al. (2023a) (opens in a new tab)
  9. Barman-Aksözen et al. (2023b) (opens in a new tab)
  10. Barman-Aksözen et al. (2026) (opens in a new tab)
  11. Bell et al. (2026) (opens in a new tab)
  12. Belongie et al. (2022) (opens in a new tab)
  13. Biolcati et al. (2015) (opens in a new tab)
  14. ClinicalTrials.gov NCT03520036 (opens in a new tab)
  15. ClinicalTrials.gov NCT03520036 (opens in a new tab)
  16. ClinicalTrials.gov NCT04402489 (opens in a new tab)
  17. ClinicalTrials.gov NCT04402489 (opens in a new tab)
  18. ClinicalTrials.gov NCT05005975 (opens in a new tab)
  19. ClinicalTrials.gov NCT05020184 (opens in a new tab)
  20. ClinicalTrials.gov NCT06144840 (opens in a new tab)
  21. ClinicalTrials.gov NCT06910358 (opens in a new tab)
  22. ClinicalTrials.gov NCT06994286 (opens in a new tab)
  23. ClinicalTrials.gov NCT07820085 (opens in a new tab)
  24. Clinuvel Pharmaceuticals (2017) (opens in a new tab)
  25. Clinuvel Pharmaceuticals (2026) (opens in a new tab)
  26. Dechant et al. (2025) (opens in a new tab)
  27. DerSarkissian et al. (2025) (opens in a new tab)
  28. Di Pierro et al. (2022) (opens in a new tab)
  29. Dickey et al. (2021) (opens in a new tab)
  30. Dickey et al. (2023) (opens in a new tab)
  31. Disc Medicine (2026) (opens in a new tab)
  32. Disc Medicine (2026) (opens in a new tab)
  33. Elder et al. (2013) (opens in a new tab)
  34. EU Clinical Trials Register (2021) (opens in a new tab)
  35. EU Clinical Trials Register (2023) (opens in a new tab)
  36. European Medicines Agency (2022) (opens in a new tab)
  37. European Medicines Agency (2025) (opens in a new tab)
  38. Gemeinsamer Bundesausschuss (2021) (opens in a new tab)
  39. GondolaBio (2025) (opens in a new tab)
  40. GondolaBio (2026) (opens in a new tab)
  41. Graziadei et al. (2022) (opens in a new tab)
  42. Holme et al. (2006) (opens in a new tab)
  43. Horizonscan Geneesmiddelen (2026) (opens in a new tab)
  44. Jaramillo-Calle (2021) (opens in a new tab)
  45. jRCT2080225355 (opens in a new tab)
  46. Kluijver et al. (2024) (opens in a new tab)
  47. Kluijver et al. (2025) (opens in a new tab)
  48. Lala et al. (2018) (opens in a new tab)
  49. Langendonk et al. (2015) (opens in a new tab)
  50. LEO Pharma (2026) (opens in a new tab)
  51. LEO Pharma (2026) (opens in a new tab)
  52. Levy et al. (2024) (opens in a new tab)
  53. Levy et al. (2025) (opens in a new tab)
  54. Madigan et al. (2023) (opens in a new tab)
  55. Mathias et al. (2023) (opens in a new tab)
  56. McNamara (2026) (opens in a new tab)
  57. Minder et al. (2025) (opens in a new tab)
  58. Mitsubishi Tanabe Pharma America (2024) (opens in a new tab)
  59. Mitsubishi Tanabe Pharma Development America (2019) (opens in a new tab)
  60. Mitsubishi Tanabe Pharma Development America (2021) (opens in a new tab)
  61. Mitsubishi Tanabe Pharma Development America (2022) (opens in a new tab)
  62. Naik et al. (2019a) (opens in a new tab)
  63. Naik et al. (2019b) (opens in a new tab)
  64. Naik et al. (2025a) (opens in a new tab)
  65. Naik et al. (2025b) (opens in a new tab)
  66. Naik et al. (2025c) (opens in a new tab)
  67. NICE (2023) (opens in a new tab)
  68. NICE (2023) (opens in a new tab)
  69. NICE (2023) (opens in a new tab)
  70. NIHR Innovation Observatory (2022) (opens in a new tab)
  71. NORD (2022) (opens in a new tab)
  72. Norwegian Medicines Agency (2018) (opens in a new tab)
  73. Ogasawara et al. (2023) (opens in a new tab)
  74. Ogasawara et al. (2024) (opens in a new tab)
  75. Ogasawara et al. (2025a) (opens in a new tab)
  76. Ogasawara et al. (2025b) (opens in a new tab)
  77. Ogawa et al. (2023) (opens in a new tab)
  78. Raef et al. (2023) (opens in a new tab)
  79. Ross et al. (2026) (opens in a new tab)
  80. Sato et al. (2024) (opens in a new tab)
  81. Silver et al. (2025) (opens in a new tab)
  82. Suzuki et al. (2022) (opens in a new tab)
  83. Tanabe Pharma America (2024) (opens in a new tab)
  84. Tanabe Pharma America (2025) (opens in a new tab)
  85. Tanabe Pharma America (2026) (opens in a new tab)
  86. Tanabe Pharma Corporation (2025) (opens in a new tab)
  87. Tanabe Pharma Corporation (2026) (opens in a new tab)
  88. Tanabe Pharma Corporation (2026) (opens in a new tab)
  89. Tanabe Pharma Corporation (2026) (opens in a new tab)
  90. Thompson et al. (2016) (opens in a new tab)
  91. Tran et al. (2025) (opens in a new tab)
  92. Tsuda et al. (2023) (opens in a new tab)
  93. US Food and Drug Administration (2019) (opens in a new tab)
  94. Ventura et al. (2020) (opens in a new tab)
  95. Wensink et al. (2020) (opens in a new tab)
  96. Wensink et al. (2021) (opens in a new tab)
  97. Wensink et al. (2022) (opens in a new tab)
  98. Wensink et al. (2023) (opens in a new tab)
  99. Whatley et al. (2010) (opens in a new tab)
  100. Yeung et al. (2026) (opens in a new tab)